Only the triple administration of anti-PD-1, anti-CTLA-4, and cisplatin (ICB + CIS) engendered durable responses in mice, and eosinophils were the only cells that consistently increased after ICB + CIS therapy in the primary and metastatic tumor, the blood, and the healthy BM (Fig. 3). Here, PDCD1 is linked to in situ carcinoma.